Auro Laboratories Share Price Today

Auro Laboratories Q1 Results: Net Profit Turns Positive At ₹10.45 Crore

Auro Laboratories Ltd turned profitable in Q1FY26, reporting a net profit of ₹104.56 lakh on a 178% YoY revenue surge to ₹887.64 lakh. The board approved the results on August 14, 2026, marking a recovery from a loss in the previous year's quarter.

Auro Laboratories Limited schedules 37th AGM on August 11, 2026

Auro Laboratories Limited will hold its 37th AGM on August 11, 2026, via video conferencing. The company has dispensed with physical annual reports, offering electronic copies and e-voting facilities to shareholders.

Auro Laboratories re-appoints Kiran Kulkarni as Whole Time Director for 3 years

Auro Laboratories Limited has approved the re-appointment of Mr. Kiran Suresh Kulkarni as Whole Time Director for a term of three years, effective from May 24, 2027, to May 23, 2030. The decision is subject to shareholder approval at the 37th Annual General Meeting scheduled for August 11, 2026. Mr. Kulkarni brings over 25 years of experience in the QC/QA department of API manufacturing companies.

Auro Laboratories CFO resigns effective May 28, 2026

Auro Laboratories Limited disclosed the resignation of its CFO, Mr. Kuntal Pancholi, effective May 28, 2026, due to personal reasons. The company confirmed there are no other material reasons for the resignation and that he ceases to be a Key Managerial Personnel under the Companies Act, 2013.

Auro Laboratories board to consider FY26 results on May 29

Auro Laboratories Limited's board is set to meet on May 29, 2026, to approve the audited financial results for the quarter and fiscal year ended March 31, 2026. The trading window for insiders has been closed since April 01, 2026, and will reopen 48 hours after the results are disclosed to the exchanges.

Auro Laboratories Receives Credit Rating Assignment from Acuite Ratings for Rs.79.80 Crore Bank Facilities

Auro Laboratories Limited received credit ratings from Acuite Ratings & Research Limited for Rs.79.80 crore bank facilities, with ACUITE BB+ stable for Rs.64.20 crore long-term facilities and ACUITE A4+ for Rs.15.60 crore short-term facilities. The ratings reflect the company's extensive promoter experience and three-decade operational track record, while considering constraints from modest operations scale and intensive working capital requirements. The pharmaceutical API manufacturer recently completed capacity expansion increasing manufacturing from 1,260 MT to 2,100 MT annually, though revenue declined to Rs.19.40 crore in FY2025 from Rs.53.64 crore in FY2024 due to the expansion period.